Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis

Yadong Guo; Yadong Guo; Anil Shrestha; Niraj Maskey; Niraj Maskey; Xiaohui Dong; Zongtai Zheng; Zongtai Zheng; Fuhan Yang; Fuhan Yang; Ruiliang Wang; Ruiliang Wang; Wenchao Ma; Wenchao Ma; Ji Liu; Ji Liu; Cheng Li; Cheng Li; Wentao Zhang; Wentao Zhang; Shiyu Mao; Shiyu Mao; Aihong Zhang; Shenghua Liu; Shenghua Liu; Xudong Yao; Xudong Yao

doi:10.3389/fendo.2022.762589

Frontiers in Endocrinology (Feb 2022)

Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis

Yadong Guo,
Yadong Guo,
Anil Shrestha,
Niraj Maskey,
Niraj Maskey,
Xiaohui Dong,
Zongtai Zheng,
Zongtai Zheng,
Fuhan Yang,
Fuhan Yang,
Ruiliang Wang,
Ruiliang Wang,
Wenchao Ma,
Wenchao Ma,
Ji Liu,
Ji Liu,
Cheng Li,
Cheng Li,
Wentao Zhang,
Wentao Zhang,
Shiyu Mao,
Shiyu Mao,
Aihong Zhang,
Shenghua Liu,
Shenghua Liu,
Xudong Yao,
Xudong Yao

Affiliations

Yadong Guo: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Yadong Guo: Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Anil Shrestha: Department of Urology, National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal
Niraj Maskey: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Niraj Maskey: Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Xiaohui Dong: Department of General Medical, Shanghai Fourth People’s Hospital, Tongji University, Shanghai, China
Zongtai Zheng: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Zongtai Zheng: Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Fuhan Yang: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Fuhan Yang: Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Ruiliang Wang: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Ruiliang Wang: Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Wenchao Ma: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Wenchao Ma: Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Ji Liu: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Ji Liu: Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Cheng Li: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Cheng Li: Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Wentao Zhang: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Wentao Zhang: Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Shiyu Mao: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Shiyu Mao: Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Aihong Zhang: Department of Medical Statistics, Tongji University School of Medicine, Shanghai, China
Shenghua Liu: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Shenghua Liu: Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Xudong Yao: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
Xudong Yao: Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China

DOI: https://doi.org/10.3389/fendo.2022.762589
Journal volume & issue: Vol. 13

Abstract

Read online

BackgroundClear cell adenocarcinoma (CCA) is considered a relatively rare tumor with a glycogen-rich phenotype. The prognosis of CCA patients is unclear. In this study, recent trends in the epidemiological and prognostic factors of CCA were comprehensively investigated.MethodsPatients with CCA from years 2000 to 2016 were identified from the Surveillance, Epidemiological, and End Results (SEER) database. Relevant population data were used to analyze the rates age-adjusted incidence, age-standardized 3-year and 5-year relative survivals, and overall survival (OS).ResultsThe age-adjusted incidence of CCA increased 2.7-fold from the year 2000 (3.3/100,000) to 2016 (8.8/100,000). This increase occurred across all ages, races, stages, and grades. Of all these subgroups, the increase was largest in the grade IV group. The age-standardized 3-year and 5-year relative survivals increased during this study period, rising by 9.1% and 9.5% from 2000 to 2011, respectively. Among all the stages and grades, the relative survival increase was greatest in the grade IV group. According to multivariate analysis of all CCA patients, predictors of OS were: age, gender, year of diagnosis, marital status, race, grade, stage, and primary tumor site (P < 0.001). The OS of all CCA patients during the period 2008 to 2016 was significantly higher than that from 2000 to 2007 (P < 0.001).ConclusionsThe incidence of CCA and survival of these patients improved over time. In particular, the highest increases were reported for grade IV CCA, which may be due to an earlier diagnosis and improved treatment.

Published in Frontiers in Endocrinology

ISSN: 1664-2392 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the endocrine glands. Clinical endocrinology
Website: https://www.frontiersin.org/journals/endocrinology

About the journal

Abstract

Keywords